New combo therapy shows promise for tough head and neck cancers
NCT ID NCT00939627
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested whether adding sorafenib to cetuximab works better than cetuximab alone for patients with advanced head and neck cancer that has come back or spread. Fifty-five adults with various types of head and neck cancer took part. The study measured how long patients lived without their cancer getting worse and how their tumors responded to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cetuximab and sorafenib tosylate
- What this could lead to
- If it works, this could point toward a more effective treatment option for patients with advanced head and neck cancer who have not responded to prior therapies.
- What could go wrong
- This is a small, early-phase trial (55 participants) that may not show a clear benefit. The combination could also cause more side effects than cetuximab alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Billings Clinic
Billings, Montana, 59107-7000, United States
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Montefiore Medical Center
The Bronx, New York, 10467-2490, United States
-
Suburban Hospital
Bethesda, Maryland, 20814, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Experimental antibody combo aims to boost immune attack on head and neck tumors
- New surgical flap aims to restore swallowing and speech in obese tongue cancer patients
- Scientists hunt for blood markers to unmask hidden aggressive tumors